化疗联合CIK细胞治疗转移性胰腺癌的临床观察  

Efficacy and safety of CIK cell therapy combined with chemotherapy in patients with pancreatic cancer

作　　者：王子兵 尚艺曼 张勇 高全立 

机构地区：[1]郑州大学附属肿瘤医院/河南省肿瘤研究院,河南郑州450008

出　　处：《实用医药杂志》2013年第11期967-968,共2页Practical Journal of Medicine & Pharmacy

基　　金：国家自然科学基金青年科学基金项目(81000914);河南省科技攻关计划重大项目(2011010011)

摘　　要：目的 观察化疗联合CIK细胞治疗转移性胰腺癌的疗效及安全性.方法 回顾性分析入住笔者所在科行化疗联合CIK细胞治疗的11例转移性胰腺癌患者的临床资料.这些患者均接受按体表面积计量的吉西他滨和/或替吉奥化疗药物,然后在化疗用药结束后的第2～5d回输CIK细胞.观察指标包括疾病控制率、中位生存时间、1年生存率和不良反应.结果 11例中无完全缓解者,3例部分缓解,6例病情稳定,2例病情进展,疾病控制率为81.82％.中位生存时间为14.87个月,1年生存率为72.73％.不良反应如下：骨髓抑制4例,腹泻2例,乏力、纳差1例.结论 化疗联合CIK细胞治疗转移性胰腺癌,疗效和耐受性较好,可明显提高患者生存时间.Objective To observe the efficacy and safety of chemotherapy and CIK cell therapy for advanced pan- creatic cancer. Methods A retrospective analysis of 11 advanced pancreatic cancer cases receiving chemotherapy com- bined with CIK cell therapy was made by authors. All these patients received gemcitabine and/or S - 1 combined with CIK cell therapy. Disease control rate, median survival time, 1 -year survival rate and adverse reaction were observed. Results Disease control rate was 81.82%, i e,no cases of CR, 3 cases of PR, 6 cases of SD, and 2 cases of PD. The median survival time was 14. 87 months and 1 - year survival rate was 72. 73%. The adverse reaction included 4 cases of hemato- logical toxicity, 2 cases of diarrhea, and 1 case of fatigue weakness. Conclusion Chemotherapy combinde with CIK cell therapy can significantly prolong survival of advancde pancreatic cancer patients.

关 键 词：胰腺癌 化疗 CIK细胞治疗 

分 类 号：R735.9[医药卫生—肿瘤]